| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NASDAQ |
| Div & Yield | N.A. (N.A) |
Compounds Transferred to Bristol-Myers Squibb for Further Development
A mid-stage study of Tranzyme's TZP-102 failed to improve stomach mobility in diabetics.
Company Completes Patient Enrollment in TZP-102 Phase 2b Trial
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
The top 10 open-market insider purchases and sales filed at the SEC Wednesday.
A series of disappointments and setbacks is cooling off the once red-hot biotech sector.
